
# Respiratory Drug Delivery VII

Biological, Pharmaceutical, Clinical and Regulatory Issues Relating to Optimized Drug Delivery by Aerosol



Palm Harbor at Tarpon Springs, Florida May 14-18, 2000

The Seventh in a Series of International Symposia Organized by the School of Pharmacy of Virginia Commonwealth University

Supplied by the British Library 05 Mar 2020, 19:32 (GMT)

Nalox1237



SPA 2/90691

## RESPIRATORY DRUG DELIVERY VII

Biological, Pharmaceutical, Clinical and Regulatory Issues Relating to Optimized Drug Delivery by Aerosol

> Volume I Conference Papers

BRITISH LONGRY
DOCUMENT SUPPLY CENTRE

2 9 SEP 2000

CONFERENCE
INDEX.

Volume II Suppliers Forum Poster Sessions

Palm Harbor at Tarpon Springs, Florida May 14 - 18, 2000

The Seventh in a Series of International Symposia Organized by the School of Pharmacy of Virginia Commonwealth University

This book belongs to:

Supplied by the British Library 05 Mar 2020, 19:32 (GMT)

Nalox1237



10987654321

ISBN: Volume I, 1-930114-14-1; Volume II, 1-930114-16-8 Copyright ® 2000 by Serentec Press, Inc. All rights reserved.

This book is protected by copyright. No part of it may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without written permission from the publisher. Printed in the United States of America.

Where a product trademark, registration mark, or other protected mark is made in the text, ownership of the mark remains with the lawful owner of the mark. No claim, intentional or otherwise, is made by reference to any such marks in this book.

While every effort has been made by Serentec Press, Inc., to ensure the accuracy of the information contained in this book, this organization accepts no responsibility for errors or omissions.

Serentec Press, Inc. 612 W. Lane Street Raleigh, North Carolina 27603 Phone: 919-831-1166 Fax: 919-831-2211

Serentec Press, Inc. Raleigh, North Carolina Chichester, England

ii



Supplied by the British Library 05 Mar 2020, 19:32 (GMT)

Nalox1237

## NANO-THIN COATINGS FOR IMPROVED LUNG TARGETING OF GLUCOCORTICOID DRY POWDERS: IN-VITRO AND IN-VIVO CHARACTERISTICS

Jim Talton<sup>1</sup>, Jim Fitz-Gerald<sup>2</sup>, Rajiv Singh<sup>3</sup>, and Günther Hochhaus<sup>1</sup>

<sup>1</sup>Department of Pharmaceutics, University of Florida, Gainesville, FL 32610. e-mail: Hochhaus@UFL.EDU; <sup>2</sup>Naval Research Laboratory Code 6372₂Surface Modification Branch, Washington, DC 20375, <sup>3</sup>Department of Materials Science and Engineering, University of Florida, Gainesville, FL 32611

### SUMMARY

A new technique for the preparation of ultra-thin coatings onto inhaled dry powders is presented. The method is based on pulsed laser deposition (PLD) of polymers such as PLGA onto dry powders by directing laser induced high-energy pulses of ultraviolet light onto the polymer. The formed plume of polymer nanoparticles is subsequently deposited onto the dry powder. The coating can be added onto standard dry powder material without the use of wet chemistry. Characterization of the coated particles by SEM and HPLC supported the nanometer-thick nature of the coatings. The deposited material did not affect cell viability in murine alveolar macrophage cell lines over controls and analysis by cascade impaction did not differ from that of uncoated material. Most notable, deposition of PLGA onto dry powders of budesonide and triamcinolone acetonide resulted in a sustained dissolution behavior of approximately 70% of the coated powders from 2 to 24 hours. This resulted in a significant improvement in pulmonary targeting when coated budesonide was compared with uncoated budesonide in a rat animal model for pulmonary targeting.

### INTRODUCTION

Inhaled drugs are delivered most commonly via dry powder or metered dose inhalers in order to achieve pulmonary targeting by inducing pronounced local effects with reduced systemic side effects. In addition to drug entity related properties such as oral bioavailability, and clearance, formulation dependent factors, such as pulmonary deposition, and pulmonary mean residence time are recognized as important key features for a successful inhaled anti-asthma drug (1, 2). In particular, computer simulations have shown that, based on receptor occupancies in individual organs, pulmonary targeting can be improved most drastically by optimization of pulmonary dissolution or release rate (1). Recently our group has experimentally shown for liposomal preparations that a slow pulmonary drug release can lead to improved pulmonary selectivity and efficacy (3). It is also likely that pulmonary administration of drugs intended for systemic use will also benefit from a slow pulmonary drug release, e.g., by allowing longer dosing intervals. Unfortunately, the lung represents an organ which is difficult to target because of the enormous blood flow and the resulting pronounced sink conditions, which favor fast pulmonary absorption, especially of small molecules (4-6). The relatively short duration of action in the lungs following inhala-



tion of a drug designed for inducing pulmonary effects and the short systemic effects of a short half-life drug inhaled for inducing systemic effects, therefore, are often the result of their rapid systemic absorption from the airways.

Sustained pulmonary delivery has been achieved with liposomal preparations (for review see [7]), slow dissolving lipophilic drugs (8), microspheres (9), and microparticles (10). The use of porous low density microspheres (11-13) and new pulmonary additives with sustained release producing effects (14) have found recent attention. This paper presents preliminary results on the assessment of an alternative method for the preparation of sustained release delivery forms by the post application of dry-coatings. Over the past few years, the pulsed laser deposition (PLD) technique has emerged as one of the simplest and most versatile methods for the deposition of thin films to a wide variety of flat surfaces (15). Recently, this process has been applied to the coating of fluidized particles, allowing the design of artificially structured, nano-functionalized coatings onto particulate materials with unique physicochemical, optical, cathodoluminescent, or electrical properties (16). This method was applied to the synthesis of pharmaceutically relevant coatings to dry powders (16, 17).

## DRY-POWDER COATING TECHNIQUE

This variation of pulsed laser deposition (PLD) uses high-energy pulses of ultraviolet light to deposit solid coating materials onto particles (Figure 1). A laser source is directed in a vacuum chamber towards the polymeric target and induces the plume formation. The generated plume then settles onto the agitated dry powder. Depending on the length of the pulsed laser treatment, either discrete entities or continuous films are deposited onto the surface of the drug particle, which will significantly modulate and enhance the properties of the material (16). Through this coating method, the coating material is generally less than 1% by mass, and coating times are under one hour without the need for drying solvents. Preliminary experiments (16, 17) with biodegradable polymers, faster-degrading poly(lactic-co-glycolic acid) (PLGA) and slower degrading poly(l-lactic acid) (PLA), coated onto micronized budesonide (BUD) and triamcinolone acetonide (TA) are reviewed here, although other coatings on different sized particles have been tested successfully as well.

## PHYSICOCHEMICAL CHARACTERIZATION

As indicated in the scheme (Figure 1), discrete clusters form for short exposure times, while longer exposure times result in the formation of a continuous film. Preliminary studies by SEM microscopy of polymer deposited on flat surfaces at different run times suggested that 100 nanometer size or less droplets are deposited (data not shown) and form continuous coatings after several minutes (Figure 2a). Also, coatings onto micronized drug particles (1-5 µm pre-coating, particles not shown) indicate that the size of coated material remains in the size range of smaller than 5 µm (Figure 2b), suggesting that pulsed laser deposition is able to apply ultra-thin coatings without affecting the primary particle size distribution.



## DOCKET

## Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## **Real-Time Litigation Alerts**



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## **Advanced Docket Research**



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## **Analytics At Your Fingertips**



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## **LAW FIRMS**

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## **FINANCIAL INSTITUTIONS**

Litigation and bankruptcy checks for companies and debtors.

## **E-DISCOVERY AND LEGAL VENDORS**

Sync your system to PACER to automate legal marketing.

